Friday, September 15, 2017 10:15 PM ET
Insider purchase at KemPharm (KMPH) prolongs buy activity of Last 90 Days
There was a substantial insider buying activity in KemPharm shares today as revealed in a filing with the SEC. One insider — Street Capital Master Fund, L.P. Delaware, 10% Owner — purchased 325,888 shares in the company having a net market value of approximately $1,066,827. There have been 3 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been buys resulting in the acquisition of 9,275 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net purchases of 335,163 shares and have averaged 83,791 shares per transaction over this time period.
During the last 90 days, the number of insider buy/sell trades at KemPharm is higher than the 266-company peer group average. Bio Therapeutic Drugs peer group saw 298 buy/sell trades during this period for an average of 1.1 transactions per company. The number of shares per buy/sell trade for KemPharm insiders was also higher. Within the peer group there were 7,660,539 shares purchased and 16,440,105 shares sold with company insiders having sold 29,462 shares on average.
Significant insider buying and selling activity has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in data sourced in evaluating and writing this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.